Legend Biotech shares data on CARVYKTI® in the treatment of multiple myeloma
Legend Biotech Corporation, a leader in cell therapy, announced positive results from its Phase 2 CARTITUDE-2 Cohort D study,...
Merck’s Innovative Oncology Pipeline Poised to Revolutionize Cancer Treatment
Merck KGaA, a science and technology leader, is expanding its oncology pipeline with promising new treatments. The company plans...
Visugromab/Nivolumab Combo Triumphs in Advanced Cancer Battle
Positive Results from CatalYm’s GDFATHER Trial CatalYm’s “GDFATHER” Phase 1/2a trial has shown promising results for its lead candidate,...
Bristol Myers Squibb Unveils Remarkable Analyses on Opdivo’s Efficacy in Non-Small Cell Lung Cancer
Bristol Myers Squibb’s ongoing research in non-small cell lung cancer (NSCLC) has yielded promising results in various stages of...
Obsidian’s OBX-115 Data Unveiled at ASCO 2024: Safety, Efficacy, and Surprises
Obsidian Therapeutics presented updated data from the Phase 1 study of OBX-115, an engineered tumor-derived autologous T-cell immunotherapy, at...
Fulgent Data: Uncovering Fid-007 in Head and Neck Cance
Fulgent Pharma, a subsidiary of Fulgent Genetics, presented data at ASCO 2024 showing promising results for their therapeutic candidate,...
FDA Selects Neurogene’s NGN-401 for Innovative Rett Syndrome Therapy Pilot Program
Neurogene Inc.’s NGN-401 gene therapy for Rett syndrome has been selected for the FDA’s Support for Clinical Trials Advancing...
Calidi Presents Phase 1 Update and Preclinical Data on Cld-101 at ASCO 2024
Calidi Biotherapeutics presented its latest developments in antitumor virotherapy at the American Society of Clinical Oncology (ASCO) Annual Meeting....
Takeda’s TAK-861 Phase 2B Data: A Breakthrough for Narcolepsy Type 1
A Phase 2b trial has demonstrated significant improvements for TAK-861, an investigational treatment for narcolepsy type 1 (NT1). The...
Summit Therapeutics $200M Raise: Exclusive Licenses Expand Ivoscimab Territories
Summit Therapeutics raised $200 million through an institutional investment, with shares sold at a premium to the previous closing...